SCHEMBL1239639

SCHEMBL1239639

Oc1c(C(c2ccc(Cl)cc2)N2CCOCC2)ccc2cccnc12

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.76
ALOX12 P18054 5/20 0.69
LMNA P02545 4/20 0.69
TP53 P04637 3/20 0.69
ALOX15 P16050 3/20 0.69
L3MBTL1 Q9Y468 2/20 0.69
HSD17B10 Q99714 2/20 0.69
PPP1CA P62136 1/20 0.69
P4HB P07237 4/20 0.63
HSP90AA1 P07900 9/20 0.58
ALDH1A1 P00352 6/20 0.58
KDM4E B2RXH2 6/20 0.58
MAPT P10636 5/20 0.58
KMT2A Q03164 4/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
HTT P42858 3/20 0.58
NPSR1 Q6W5P4 3/20 0.58
TDP1 Q9NUW8 3/20 0.58
S1PR4 O95977 1/20 0.58
S1PR1 P21453 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30253905 0.90 ALOX12 (0.77) BRAFALOX12LMNATP53ALOX15
SCHEMBL11955274 0.90 ALOX12 (0.77) BRAFALOX12LMNATP53ALOX15
SCHEMBL9956784 0.89 BRAF (0.79) BRAFALOX12LMNATP53ALOX15
SCHEMBL11895967 0.89 P4HB (0.80) BRAFALOX12LMNATP53ALOX15
SCHEMBL1239504 0.89 BRAF (0.75) BRAFALOX12LMNATP53ALOX15
SCHEMBL16696547 0.89 P4HB (0.79) BRAFALOX12LMNATP53ALOX15
SCHEMBL11955336 0.86 BRAF (0.71) BRAFALOX12LMNATP53ALOX15
SCHEMBL16696529 0.86 HSP90AA1 (0.74) BRAFALOX12LMNATP53ALOX15
SCHEMBL1239593 0.86 BRAF (1.00) BRAFALOX12LMNATP53ALOX15
SCHEMBL1237893 0.86 BRAF (0.71) BRAFALOX12LMNATP53ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120196853-A1 Novel Quinoline-Hepcidine Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-02 US disclosed
US-20120196853-A1 Novel Quinoline-Hepcidine Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-02 US disclosed
US-20120196853-A1 Novel Quinoline-Hepcidine Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-02 US disclosed
EP-2467361-A1 NOVEL QUINOLINE-HEPCIDINE ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2012-06-27 EP disclosed
WO-2011020886-A1 NOVEL QUINOLINE-HEPCIDINE ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2011-02-24 WO disclosed
WO-2011020886-A1 NOVEL QUINOLINE-HEPCIDINE ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2011-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196853-A1 Novel Quinoline-Hepcidine Antagonists HAMP, SLC40A1, FTH1 BRAF 4398/4885ALOX12 251/4885LMNA 3466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.